Published in Eur Respir J on December 08, 2009
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.00
Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog (2012) 1.91
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J (2015) 1.60
Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. PLoS One (2015) 1.48
Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest (2014) 1.25
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J (2010) 1.18
A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis (2013) 1.18
Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab (2011) 1.13
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res (2013) 1.10
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res (2011) 1.06
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs (2011) 1.03
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med (2014) 1.02
Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med (2013) 1.02
Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther (2010) 1.02
Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2014) 0.99
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res (2011) 0.98
Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients. BMC Pulm Med (2012) 0.98
TGF-β signaling via TAK1 pathway: role in kidney fibrosis. Semin Nephrol (2012) 0.96
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (2014) 0.96
Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci (2012) 0.95
Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med (2012) 0.95
Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol (2013) 0.94
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther (2014) 0.94
Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res (2014) 0.93
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol (2014) 0.92
Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol (2011) 0.92
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res (2016) 0.92
Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol (2015) 0.92
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One (2012) 0.89
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Recommendations on treatment for IPF. Respir Res (2013) 0.86
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res (2013) 0.85
Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP. J Inflamm (Lond) (2012) 0.85
Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer. Pulm Med (2011) 0.85
The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir Res (2013) 0.85
Protein tyrosine phosphatase α mediates profibrotic signaling in lung fibroblasts through TGF-β responsiveness. Am J Pathol (2014) 0.85
High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res (2014) 0.84
Pharmacokinetics of pirfenidone after topical administration in rabbit eye. Mol Vis (2011) 0.84
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2010) 0.84
Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today (2014) 0.84
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int (2015) 0.83
IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Adv Ther (2015) 0.83
Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell. Mol Cells (2014) 0.83
Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res (2013) 0.83
Pirfenidone. Nat Rev Drug Discov (2011) 0.83
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther (2013) 0.83
Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2011) 0.83
Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema. Lung (2013) 0.83
Diagnosis and management of interstitial lung disease. Transl Respir Med (2014) 0.83
Idiopathic pulmonary fibrosis: early detection and referral. Respir Med (2014) 0.82
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis (2015) 0.81
Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine (Baltimore) (2015) 0.81
Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur Clin Respir J (2015) 0.80
Cell-based therapy in lung regenerative medicine. Regen Med Res (2014) 0.80
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis (2015) 0.80
Where do we stand with IPF treatment? Respir Res (2013) 0.80
Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis. BMC Pulm Med (2015) 0.80
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med (2016) 0.79
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence (2014) 0.79
Approach to acute exacerbation of idiopathic pulmonary fibrosis. Ann Thorac Med (2013) 0.79
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther (2015) 0.79
Preparation of novel pirfenidone microspheres for lung-targeted delivery: in vitro and in vivo study. Drug Des Devel Ther (2016) 0.79
Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability. BMC Pulm Med (2014) 0.79
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest (2015) 0.79
New perspectives on management of idiopathic pulmonary fibrosis. Ther Adv Chronic Dis (2016) 0.79
Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. Adv Ther (2015) 0.79
Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1β/IL-1R1/MyD88/NF-κB pathway. J Cell Mol Med (2016) 0.79
Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis. Biomed Res Int (2013) 0.78
The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int (2013) 0.78
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Clinical trials and tribulations--lessons from pulmonary fibrosis. QJM (2012) 0.78
Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid (2015) 0.78
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.77
Advances in the management of idiopathic pulmonary fibrosis. F1000 Med Rep (2010) 0.77
Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int (2012) 0.76
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis (2016) 0.76
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.76
Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society. J Thorac Dis (2016) 0.76
Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respir Res (2016) 0.75
A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article. Medicine (Baltimore) (2016) 0.75
TGF-β-activated kinase-1: New insights into the mechanism of TGF-β signaling and kidney disease. Kidney Res Clin Pract (2012) 0.75
Effect of stem cell therapy on amiodarone induced fibrosing interstitial lung disease in albino rat. Int J Stem Cells (2011) 0.75
Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J (2016) 0.75
Clinical trials of investigational agents for IPF: a review of a Cochrane report. Respir Res (2013) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med (2015) 0.75
Increased Cellular NAD(+) Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice. Tuberc Respir Dis (Seoul) (2016) 0.75
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid (2016) 0.75
Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep (2016) 0.75
Silicosis Appears Inevitable Among Former Denim Sandblasters: A 4-Year Follow-up Study. Chest (2015) 0.75
A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study. Eur Clin Respir J (2016) 0.75
The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med (2015) 0.75
Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience. Ann Thorac Med (2015) 0.75
The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis. JCI Insight (2016) 0.75
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A (2003) 14.01
Primary structure of Electrophorus electricus sodium channel deduced from cDNA sequence. Nature (1984) 8.02
Existence of distinct sodium channel messenger RNAs in rat brain. Nature (1986) 7.87
Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet (1997) 7.59
TRAF6 is a signal transducer for interleukin-1. Nature (1996) 7.38
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature (1987) 6.66
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 5.65
Chromosome partitioning in Escherichia coli: novel mutants producing anucleate cells. J Bacteriol (1989) 5.43
Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A (1986) 5.18
Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature (1986) 4.97
Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol (2001) 4.96
Heterogeneity of the principal sigma factor in Escherichia coli: the rpoS gene product, sigma 38, is a second principal sigma factor of RNA polymerase in stationary-phase Escherichia coli. Proc Natl Acad Sci U S A (1993) 4.92
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother (1989) 4.79
Structural homology of Torpedo californica acetylcholine receptor subunits. Nature (1983) 4.70
Partition mechanism of F plasmid: two plasmid gene-encoded products and a cis-acting region are involved in partition. Cell (1983) 4.39
Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet (1994) 4.36
Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 4.13
Mini-F plasmid genes that couple host cell division to plasmid proliferation. Proc Natl Acad Sci U S A (1983) 4.07
SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother (1978) 4.06
Binding of neuroligins to PSD-95. Science (1997) 3.88
The new gene mukB codes for a 177 kd protein with coiled-coil domains involved in chromosome partitioning of E. coli. EMBO J (1991) 3.86
Fission yeast cut3 and cut14, members of a ubiquitous protein family, are required for chromosome condensation and segregation in mitosis. EMBO J (1994) 3.83
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
Primary structure of alpha-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature (1982) 3.69
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64
K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun (1987) 3.46
Transient mutism resolving into cerebellar speech after brain stem infarction following a traumatic injury of the vertebral artery in a child. Acta Neurochir (Wien) (1999) 3.37
Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med (1999) 3.36
Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell (2001) 3.29
Primary structure of the alpha-subunit of transducin and its relationship to ras proteins. Nature (1985) 3.28
Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat Genet (2001) 3.14
Effects of the ccd function of the F plasmid on bacterial growth. J Bacteriol (1985) 3.10
Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature (1982) 3.09
Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet (1996) 3.07
Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother (1981) 3.03
Modified formalin test: characteristic biphasic pain response. Pain (1989) 3.00
Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int (2006) 3.00
Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun (2001) 2.86
The HLA system. Second of two parts. N Engl J Med (2000) 2.80
Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature (1982) 2.79
A consensus linkage map of the chicken genome. Genome Res (2000) 2.79
Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor. Nature (1983) 2.78
Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. J Cell Biol (2001) 2.73
Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med (1998) 2.69
Mechanism of action of globomycin. J Antibiot (Tokyo) (1978) 2.66
Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med (1995) 2.63
The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A (1996) 2.62
Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res (1994) 2.61
Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature (2000) 2.60
Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A (1993) 2.58
Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science (1991) 2.56
Primary structures of beta- and delta-subunit precursors of Torpedo californica acetylcholine receptor deduced from cDNA sequences. Nature (1983) 2.55
Structure and function of the F plasmid genes essential for partitioning. J Mol Biol (1986) 2.53
Cloning and nucleotide sequence of phoP, the regulatory gene for alkaline phosphatase and phosphodiesterase in Bacillus subtilis. J Bacteriol (1987) 2.52
Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med (1999) 2.51
A spin-valve-like magnetoresistance of an antiferromagnet-based tunnel junction. Nat Mater (2011) 2.47
Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci U S A (1996) 2.46
Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest (1997) 2.44
Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development (2001) 2.42
Periodic emission from the gamma-ray binary 1FGL J1018.6-5856. Science (2012) 2.40
Location of functional regions of acetylcholine receptor alpha-subunit by site-directed mutagenesis. Nature (1985) 2.40
Molecular basis of alpha-1-antitrypsin deficiency. Am J Med (1988) 2.40
Primary structure of rat brain sodium channel III deduced from the cDNA sequence. FEBS Lett (1988) 2.39
Structure of the 5' upstream region and the regulation of the rpoS gene of Escherichia coli. Mol Gen Genet (1994) 2.38
The HLA system. First of two parts. N Engl J Med (2000) 2.33
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat (2011) 2.30
Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J Virol (1989) 2.28
Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res (1987) 2.27
Assessment of health-related quality of life in patients with interstitial lung disease. Chest (1999) 2.21
Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. Gastroenterology (1994) 2.20
Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun (1997) 2.20
The Escherichia coli FtsH protein is a prokaryotic member of a protein family of putative ATPases involved in membrane functions, cell cycle control, and gene expression. J Bacteriol (1993) 2.19
Inorganic polyphosphate and the induction of rpoS expression. Proc Natl Acad Sci U S A (1997) 2.19
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19
Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol (1991) 2.17
Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH. Clin Chem (1995) 2.15
A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet (2008) 2.15
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest (1992) 2.13
RTX toxins recognize a beta2 integrin on the surface of human target cells. J Biol Chem (1997) 2.12
E.coli MukB protein involved in chromosome partition forms a homodimer with a rod-and-hinge structure having DNA binding and ATP/GTP binding activities. EMBO J (1992) 2.12
Diastolic paradoxic jet flow in patients with hypertrophic cardiomyopathy: evidence of concealed apical asynergy with cavity obliteration. J Am Coll Cardiol (1992) 2.12
Low carbohydrate intake before oral glucose-tolerance tests. Lancet (1998) 2.11
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer (2001) 2.10
Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10
Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest (1999) 2.09
An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 2.08
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest (2001) 2.07
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis (2000) 2.07
Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res (2001) 2.06
Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation (1998) 2.05